Select Studies Reporting Survival in G3 NENs After Treatment with PRRT, 2017
| Study | Total no. patients (N) | N: Ki-67 or differentiation | Tumor primary site | PRRT type administered | PRRT dose reported | Outcome |
| Thang et al. 2017 (31) | 28 | 22: Ki-67 ≤ 55% | 17 panc, 5 small bowel, 3 large bowel, 2 bronchial, 1 unknown | 177Lu DOTATATE (median, 4 cycles) | Median cumulative activity 177Lu: 24.4 GBq at 6- to 10-wk intervals | Median PFS of 9 mo, median OS of 19 mo |
| 6: Ki-67 > 55% | Some patients with bulky disease (>4 cm); 90Y | Median cumulative activity Y: 5.1 GBq for bulky disease | Ki-67 ≤ 55%, median PFS of 12 mo, OS of 46 mo | |||
| Cycles 2–4 included radiosensitizing chemo: 5FU or capecitabine, or capecitabine temozolomide in pancreatic (n = 20) | Ki-67 > 55%, median PFS of 4 mo, OS of 7 mo | |||||
| Based on CT (n = 23): 8/23 with PR, 9/23 with stable disease, 6/23 with PD | ||||||
| Yalchin 2017 (35) | 133 (histology in 94) | 2: Ki-67 > 20% | Midgut | 90Y in 83.5% (3 average cycles) | Fixed 7.4 GBq of 90Y or 177Lu at 3-mo intervals | 2/2 patients with PD or death |
| 177Lu in 16.5% | HR: Ki-67 > 10% and PFS (HR, 2.51; 95% CI, 1.3–4.8) | |||||
| HR: Ki-67 > 10% and OS (HR, 4.3; 95% CI, 2.1–8.4) | ||||||
| Katona et al. 2017 (36) | 28 | 7: Ki-67 > 20% | Panc, lung, GI, unknown | 34% 90Y, 25% 177Lu, 41% both (2.2 average cycles) | Average 90Y of 5.92 GBq | Median PFS of 5 mo |
| Average 177Lu of 7.4 GBq | PD associated with G3: HR 3.41 (95% CI, 1.13–10.4) | |||||
| Death associated with G3: HR, 3.61 (96% CI, 1.04–12.6) | ||||||
| Kong et al. 2017 (38) | 26 | 3: Ki-67 > 20% | Panc, GI, lung, unknown | 1–2 cycles 90Y followed by 2–3 cycles 177Lu-DOTATATE (4 total cycles) | Median cumulative: 6.5 GBq 90Y and 21 GBq 177Lu | No specific comment |
Panc = pancreatic; GI = gastrointestinal; diff = differentiated; PR = partial response; PD = progressive disease; In = indium; CI = confidence interval.